Sanofi Spotlights Nirsevimab In RSV, Further Dupixent Development
Oncology Sales Growing
Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.
You may also be interested in...
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.
A week after getting the thumbs-up from the CHMP for tralokinumab, the Denmark-based dermatology specialist has been hit by a complete response letter from US regulators requesting more data about a device component of the IL-13 inhibitor.
The French drugmaker's follow up to Myozyme – avalglucosidase alfa – is in line for a potential US approval by May next year after the US FDA agreed to a speedy review of the enzyme replacement therapy, unlike its European counterparts.